BBA
SWTX

Baker Bros. Advisors’s SpringWorks Therapeutics SWTX Stock Holding History

Baker Bros. Advisors’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,999,846
Closed -$69.4M – 99
2023
Q3 		$69.4M Hold
2,999,846
– – 0.4% 18
2023
Q2 		$78.7M Buy
2,999,846
+246,344
+9% +$6.47M 0.46% 18
2023
Q1 		$70.9M Buy
2,753,502
+1,224,964
+80% +$35.8M 0.39% 16
2022
Q4 		$39.8M Buy
+1,528,538
New +$37.7M 0.24% 28

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baker Bros. Advisors's SWTX Position: Q4 2023 in Review

Baker Bros. Advisors sold out of SpringWorks Therapeutics (SWTX) in Q4 2023, closing a stake of 2,999,846 shares — an estimated $69.4M sold.

Baker Bros. Advisors first reported a position in SWTX in Q4 2022 and held it in 4 quarters. The position peaked at $78.7M in Q2 2023. 180 funds tracked by Wall St. Rank hold SWTX as of Q4 2023.

  • Baker Bros. Advisors reported no remaining SpringWorks Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Baker Bros. Advisors sold 2,999,846 SpringWorks Therapeutics shares in Q4 2023, an estimated $69.4M.
  • Baker Bros. Advisors first reported a position in SpringWorks Therapeutics in Q4 2022 and held it in 4 quarters.
  • Baker Bros. Advisors's SpringWorks Therapeutics position peaked at $78.7M in Q2 2023.
  • 180 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2023.

Based on Baker Bros. Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.